CD5 by IHC-12376 - Technical only, 12379 - Technical & Interpretation

Test info

  
CD5 by IHC
  
12376 - Technical only, 12379 - Technical & Interpretation
  
LAB12376
LAB12379
  
  • All IHC stains will include a positive control tissue
  
  • CD5 is useful in a panel of immunostains (on frozen and/or paraffin sections) to differentiate between various types of low grade B-cell lymphoma (CLL/WDLL and IDL/mantle cell lymphomas are positive)
  • CD5 should always be interpreted in conjunction with other T-cell markers and considered as positive (on B-cells) if the staining is present in areas otherwise negative for other T-cell antigens
  • The absence of CD5 reactivity in the above mentioned small cell lymphocytic malignancies significantly correlated with extra-nodal presentation
  • CD5 may be helpful in the differential of mediastinal tumors; thymic carcinomas are positive, squamous cell carcinomas are negative

Specimen

  
Tissue
  

Submit a formalin-fixed, paraffin embedded tissue block

  

Formalin-fixed, paraffin embedded (FFPE) tissue block

  

FFPE tissue section mounted on a charged, unstained slide

  

Ambient (preferred)

  
  • Unlabeled/mislabeled block
  • Insufficient tissue
  • Slides broken beyond repair

Performance

  
AHL - Immunohistochemistry
  
Mo - Fr
  
1 - 2 days
  

Immunohistochemical staining and microscopic examination

Clinical and Interpretive info

  

If requested, an interpretive report will be provided

  

Specifications

  • CD5 is a 67 kD cell membrane glycoprotein
  • CD5 reacts with normal T cells, a small subset of normal B lymphocytes and neoplastic B lymphocytes in certain low grade B cell lymphomas
  • CD5 can also react with mesotheliomas, but shows intracytoplasmic staining rather than cell membrane based staining

 
Staining pattern

  • Cell membrane (intracytoplasmic staining seen in mesotheliomas)

References

  1. Arber DA et al: CD5: a review. Appl Immunohistochemistry. 1995; 3:1-22.
  2. Tjateyama H et al: Immunoreactivity of a new CD5 antibody with normal epithelium and malignant tumors including thymic carcinoma. Am J Clin Pathol 1999; 111:235-240.

Billing

  
88342 - 1st stain
88341 - each additional stain

Tracking

  
05/15/2017
  
10/18/2018
  
01/12/2024